Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

US Patent RE46631 · Granted Dec 12, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Development of dengue virus vaccine components2025
Development of dengue virus vaccine components2025
Development of dengue virus vaccine components2025
Development of dengue virus vaccine components2025
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-2023
Development of dengue virus vaccine components2023